Nektar Therapeutics (NKTR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Arthur He CFA from H.C. Wainwright maintained a Buy rating on the stock and has a $6.50 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arthur He CFA’s rating is based on the anticipation of significant catalysts from Nektar Therapeutics’ ongoing clinical trials. The company’s REZOLVE-AD Phase 2b study, which evaluates the efficacy of rezpeg in treating moderate-to-severe atopic dermatitis, is expected to report topline results in June. This study, having completed enrollment with 396 patients, is seen as a major potential driver for the stock due to its strong scientific rationale and promising Phase 1b data. The successful achievement of the primary endpoint could significantly impact Nektar’s market position.
Additionally, the REZOLVE-AA study, investigating rezpeg for alopecia areata, is another key factor in the Buy rating. With topline data expected in December, this trial could further boost the stock if the results are positive. Despite reporting lower-than-expected financial results for 1Q25, Nektar’s cash reserves are deemed adequate to support operations into the fourth quarter of 2026, providing a stable financial outlook. These elements combined suggest a promising growth trajectory for Nektar, justifying the Buy recommendation.
In another report released on May 9, BTIG also reiterated a Buy rating on the stock with a $4.00 price target.